Intervention not reported
All‐cause deaths · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention probably leads to lower all‐cause deaths (moderate certainty).
1 finding from 1 review
Supplementation with beta‐carotene + vit C + vit E Overall cognitive functioning · cognitively healthy people in mid and late life
2 findings from 1 review
Incidence of dementia · cognitively healthy people in mid and late life
1 finding from 1 review
Cognitive function · cognitively healthy people in mid and late life
1 finding from 1 review
Incidence of dementia or MCI · cognitively healthy people in mid and late life
1 finding from 1 review
Neovascular AMD · general population
It is very uncertain whether beta‐carotene changes neovascular AMD compared with placebo (very low certainty).
1 finding from 1 review
Geographic atrophy · general population
It is very uncertain whether beta‐carotene changes geographic atrophy compared with placebo (very low certainty).
1 finding from 1 review
Quality of life · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · general population
1 finding from 1 review
no estimate extracted
Studies not reported
High
Resource use and costs · general population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any AMD · general population
Beta‐carotene showed no clear difference in any AMD compared with placebo (high certainty).
1 finding from 1 review
Progression to late AMD (neovascular AMD, geographic atrophy or both) · general population
Beta‐carotene showed no clear difference in late AMD (either neovascular AMD or geographic atrophy or both) compared with placebo (moderate certainty).
1 finding from 1 review
Recurrent VTE · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in incidence of recurrent VTE (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).
1 finding from 1 review
Mortality (treatment duration 3 months) · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE
LMWH showed no clear difference in mortality (treatment duration 3 months) compared with VKA (moderate certainty).
1 finding from 1 review
Intervention not reported
HIV infection status of the child · HIV‐positive women during pregnancy and immediate postpartum period
The intervention showed no clear difference in HIV infection status of the child (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean birthweight · HIV‐positive women during pregnancy and immediate postpartum period
The intervention showed no clear difference in mean birthweight (low certainty).
1 finding from 1 review
Intervention not reported
Low birthweight · HIV‐positive women during pregnancy and immediate postpartum period
The intervention probably leads to lower low birthweight (moderate certainty).
1 finding from 1 review
Intervention not reported
Child death by two years of age · HIV‐positive women during pregnancy and immediate postpartum period
The intervention showed no clear difference in child death by two years of age (low certainty).
1 finding from 1 review
Intervention not reported
Preterm delivery · HIV‐positive women during pregnancy and immediate postpartum period
It is very uncertain whether the intervention changes preterm delivery (very low certainty).
1 finding from 1 review